Welcome to our dedicated page for Chemomab Therapeutics news (Ticker: CMMB), a resource for investors and traders seeking the latest updates and insights on Chemomab Therapeutics stock.
Chemomab Therapeutics Ltd. (Nasdaq: CMMB) is a clinical-stage biotechnology company focused on the development of innovative therapeutics to treat fibro-inflammatory diseases with significant unmet medical needs. The company's proprietary platform centers on CM-101, a first-in-class monoclonal antibody that targets the protein CCL24, a key regulator of inflammatory and fibrotic pathways in several severe diseases.
CM-101 has demonstrated potential in disrupting the underlying biology of fibrosis through a novel mechanism of action. The company is actively advancing CM-101 through multiple Phase 2 clinical trials aimed at treating rare and life-threatening conditions such as primary sclerosing cholangitis (PSC), non-alcoholic steatohepatitis (NASH), and systemic sclerosis (SSc). In recognition of its innovative approach, CM-101 has been granted Orphan Drug designation in both the U.S. and the European Union, and it recently received Fast Track designation from the FDA for PSC treatment.
Chemomab has reported encouraging preliminary results from these trials, which indicate that CM-101 is safe and effective in interfering with fibrotic and inflammatory pathways. The company has secured robust intellectual property protections for CM-101, with patents granted or pending in major territories worldwide, ensuring proprietary rights for the treatment of multiple indications until at least 2038.
Recent highlights from Chemomab include:
- Completion of patient enrollment in the Phase 2 PSC trial, with topline data expected mid-2024.
- Granting of new patents in Brazil, Israel, and Europe that further protect the use of CM-101 in treating liver diseases and other conditions.
- Publication of peer-reviewed studies validating the role of CCL24 in driving PSC and SSc pathologies, and the potential of CM-101 as a therapeutic intervention.
- Presentations at major scientific conferences including EASL 2024 and the Gordon Research Conference, showcasing novel translational assays and proteomic profiling studies that support the efficacy of CM-101.
As Chemomab continues to advance its clinical programs and expand its scientific understanding of fibro-inflammatory diseases, it remains committed to addressing the urgent need for effective treatments in these challenging medical areas.
Chemomab Therapeutics (Nasdaq: CMMB) has successfully completed its End-of-Phase 2 Meeting with the FDA, securing alignment on a single Phase 3 registration study design for nebokitug in Primary Sclerosing Cholangitis (PSC). The Phase 3 trial will require approximately 350 PSC patients and focus on time-to-first-event of well-characterized PSC clinical events, without requiring liver biopsies or additional confirmatory studies.
The streamlined approval pathway could potentially make nebokitug the first FDA-approved treatment for PSC. The trial design is supported by published PSC data linking biomarker improvements seen in the Phase 2 SPRING trial with reduced clinical events. The company expects to report topline data from the SPRING trial's open label extension by the end of Q1 and potentially launch the Phase 3 program before year-end.
The company is currently in discussions with potential strategic partners while preparing for the Phase 3 trial, which is estimated to require about two years for participants to experience clinically-meaningful events.
Chemomab Therapeutics (Nasdaq: CMMB) has announced its participation in the virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11, 2025. CEO Dr. Adi Mor and senior management will deliver a corporate presentation at 8:00 am ET, which will be webcast live and available on the company's website for 90 days.
Chemomab is advancing CM-101, a first-in-class monoclonal antibody targeting CCL24, for fibro-inflammatory diseases. The company recently reported positive results from its Phase 2 SPRING trial in primary sclerosing cholangitis (PSC). Two key milestones are expected in early 2025: establishing an FDA registrational pathway for CM-101's Phase 3 pivotal trial and reporting data from the SPRING trial open label extension.
The company plans to initiate the PSC Phase 3 trial by year-end. CM-101 has received FDA and EMA Orphan Drug and FDA Fast Track designations for PSC treatment. Additionally, their CM-101 program for systemic sclerosis is Phase 2-ready with an open U.S. IND.
Chemomab Therapeutics (Nasdaq: CMMB), a clinical stage biotech company focused on fibro-inflammatory diseases, announces its participation in Oppenheimer's Movers in Rare Disease Summit on December 12, 2024, at the Westin Grand Central in New York City. The invitation-only event will showcase companies with potential near-term stock-moving catalysts through panels, presentations, and one-on-one investor meetings. Chemomab's management will deliver an Elevator Pitch at 2:45-3:30 pm EST and will be available for individual meetings with registered attendees.
Chemomab Therapeutics presented Phase 2 SPRING trial data for CM-101 in primary sclerosing cholangitis (PSC) at AASLD The Liver Meeting® 2024. The trial, involving 76 patients, tested two doses (10 mg/kg and 20 mg/kg) administered every three weeks over 15 weeks. CM-101 met its primary safety endpoint and showed dose-dependent improvements across multiple biomarkers. The higher 20 mg/kg dose demonstrated greater improvements, particularly in patients with moderate/advanced disease, showing anti-fibrotic, anti-inflammatory, and anti-cholestatic effects. Key improvements were observed in liver stiffness, ELF scores, PRO-C3 levels, liver biochemistries, bilirubin levels, and pruritus scores.
Chemomab Therapeutics (Nasdaq: CMMB) reported Q3 2024 financial results and announced key developments. The company has scheduled an FDA End-of-Phase 2 Meeting in Q4 2024 to discuss CM-101's Phase 3 trial design for Primary Sclerosing Cholangitis (PSC). Their cash position stands at $19.5 million as of September 30, 2024, with runway extended to early 2026 following a $10 million private placement. Q3 net loss was $3.5 million, with R&D expenses at $2.8 million and G&A expenses at $0.9 million. The company reported positive Phase 2 SPRING trial results for CM-101 in PSC patients, with plans to advance to Phase 3 in late 2025.
Chemomab Therapeutics (Nasdaq: CMMB), a clinical stage biotech company focused on fibro-inflammatory disease treatments, announced it will release its Q3 2024 financial results and business update on November 14, 2024, at 7:00 am ET. Investors interested in discussing the results after the release can contact the company via IR@chemomab.com.
Chemomab Therapeutics (Nasdaq: CMMB) announced that its late-breaking abstract on the Phase 2 SPRING trial results for CM-101 in primary sclerosing cholangitis (PSC) has been selected for an oral presentation at the AASLD The Liver Meeting® 2024. The conference will be held in San Diego from November 15-19, 2024.
Professor Christopher Bowlus, MD, FAASLD, from the University of California Davis School of Medicine, will present the data from the double-blinded portion of the trial. The presentation, titled 'CM-101 improved fibrosis biomarkers in patients with primary sclerosing cholangitis: The Phase 2 SPRING Study', is scheduled for November 18, 2024, from 2:45-3:00pm PT during the Late Breaking Abstract Parallel Session 1.
Chemomab Therapeutics (Nasdaq: CMMB), a clinical stage biotechnology company focused on fibro-inflammatory diseases, has announced its participation in two upcoming investor conferences. The company will attend the Third Annual ROTH Healthcare Opportunities Conference on October 9, 2024, in New York City, where management will meet with investors. Additionally, CEO Dr. Adi Mor will participate in a fireside chat at the Maxim Healthcare Virtual Summit on October 16, 2024, at 9:00 am ET.
The ROTH conference will feature one-on-one meetings with investors, while the Maxim Healthcare Summit will include a virtual fireside chat. A recording of the Maxim Summit fireside chat will be made available on Chemomab's investor relations website after the event. Both conferences are invitation-only events.
Chemomab Therapeutics (Nasdaq: CMMB), a clinical stage biotechnology company focused on fibro-inflammatory diseases, has announced upcoming investor conference presentations. CEO Dr. Adi Mor will deliver corporate presentations at two events:
1. H.C. Wainwright 26th Annual Global Investment Conference: A prerecorded webcast available from September 9, 2024, at 7:00 am ET for 90 days.
2. HBM Biopharma Summit 2024 in Zurich, Switzerland: A live in-person presentation scheduled for September 23, 2024, at 10:45 am CET at the Park Hyatt Zurich.
The H.C. Wainwright presentation will be accessible via webcast, while the HBM Summit presentation will not be webcast. These presentations offer investors insights into Chemomab's innovative therapeutics for high unmet need fibro-inflammatory diseases.
Chemomab Therapeutics (Nasdaq: CMMB) reported positive Phase 2 results for CM-101 in Primary Sclerosing Cholangitis (PSC), demonstrating safety and anti-fibrotic, anti-inflammatory, and anti-cholestatic activity. The company completed a $10 million PIPE financing, extending its cash runway through early 2026. Key highlights include:
- CM-101 met primary and secondary endpoints in the SPRING trial
- First therapy to show broad effects on PSC's main components
- Statistically significant reduction in liver stiffness after 15 weeks
- Planning for Phase 3 PSC trial and FDA discussions
- Q2 2024 financials: $12.8 million cash position, $2.9 million R&D expenses, $0.8 million G&A expenses
- Net loss of $3.6 million or $0.01 per share
FAQ
What is the current stock price of Chemomab Therapeutics (CMMB)?
What is the market cap of Chemomab Therapeutics (CMMB)?
What is Chemomab Therapeutics Ltd.?
What is CM-101?
What diseases is CM-101 being tested for?
Has CM-101 received any special designations from regulatory authorities?
When are the results from the Phase 2 PSC trial expected?
What recent achievements has Chemomab announced?
What makes CM-101 unique?
What is the significance of the new patents granted to Chemomab?
Where has Chemomab presented its research?
How does CM-101 work?
